TP63 and PML

  • Number of citations of the paper that reports this interaction (PMID 16007146)
  • 9
  • Data Source:
  • BioGRID (affinity chromatography technology, pull down)

TP63

PML

Gene Name tumor protein p63 promyelocytic leukemia
Image
Gene Ontology Annotations Cellular Component
Molecular Function
Biological Process
Pathways
Drugs
Diseases
GWAS
Protein-Protein Interactions 32 interactors: BAG6 BTRC CCNC CDKN2A COPS6 DAXX EMX1 EP300 GCGR GNB2L1 GRB2 HIPK2 HNRNPAB HP HPX ITIH4 KAT2B MDM4 NIPSNAP3A ORM1 PINX1 PML PPP1R13B PPP2R5A RCHY1 SCAF4 SLC35A3 TP53 TP73 UBE2I WT1 YAP1 101 interactors: ADH1B ANKRD2 ARID3A ARNT ATF2 ATXN1 AURKA AXIN1 BANP BCL2 BCL6 CASP8AP2 CCNT1 CDK1 CDK2 CDK6 CHFR CREBBP CSNK2A1 DAXX EGFR EIF4E ELF4 EP300 FOS GATA2 HDAC1 HDAC2 HDAC3 HHEX HIPK2 HTT KAT5 KAT6A MAPK11 MAPK14 MDM2 MED7 MXD1 MYB MYC NCOA2 NCOR1 NCOR2 NFKB1 NR3C1 NR4A1 PAWR PAXIP1 PCBD2 PIAS1 PIAS2 PIN1 PLAGL1 PLSCR1 POLR2E PPARG PSMA3 RARA RB1 RBX1 RELA RNF111 RNF125 RNF4 RPL11 RXRA SENP2 SH3GL1 SIAH2 SIN3A SIRT1 SKI SMAD3 SP1 SP100 SRF STAT3 SUMO1 SUMO2 SUMO3 SUV39H1 SYNE2 TDG TERF2IP TGFBR1 TGFBR2 TGIF1 THRA TOPBP1 TP53 TP63 TP73 TRIM24 TRIM27 TRIM69 UBE2I UBE2U UBE3A ZBTB16 ZFYVE9
Entrez ID 8626 5371
HPRD ID 04469 00023
Ensembl ID ENSG00000073282 ENSG00000140464
Uniprot IDs C9D7D0 Q9H3D4 P29590
PDB IDs 1RG6 2RMN 2Y9T 2Y9U 3QYM 3QYN 3US0 3US1 3US2 3ZY0 3ZY1 4A9Z 1BOR
Enriched GO Terms of Interacting Partners?
Tagcloud ?
adenocarcinomas  advantages  ago  aiding  apply  complexity  discrepant  emerge  emphasize  experimentally  generalisations  gives  haematological  isoform  lymphomas  methodologies  mis  np63  np73  p73  reagents  sense  sometimes  tap63  tap73  themes  translocations  universally 
anthracycline  apl  approaches  appropriately  arsenic  corepressors  curable  cure  deacetylase  effectiveness  explain  explains  incorporation  minority  oncogenes  pathogenetic  plzf  progranulocytic  promoters  ra  rar  recruit  refinement  relapsed  repression  safe  timed  trioxide  vast 
Tagcloud (Difference) ?
adenocarcinomas  advantages  ago  aiding  apply  complexity  discrepant  emerge  emphasize  experimentally  generalisations  gives  haematological  isoform  lymphomas  methodologies  mis  np63  np73  p73  reagents  sense  sometimes  tap63  tap73  themes  translocations  universally 
anthracycline  apl  approaches  appropriately  arsenic  corepressors  curable  cure  deacetylase  effectiveness  explain  explains  incorporation  minority  oncogenes  pathogenetic  plzf  progranulocytic  promoters  ra  rar  recruit  refinement  relapsed  repression  safe  timed  trioxide  vast 
Tagcloud (Intersection) ?